vs
ANGIODYNAMICS INC（ANGO）与3M（MMM）财务数据对比。点击上方公司名可切换其他公司
3M的季度营收约是ANGIODYNAMICS INC的75.9倍（$6.0B vs $79.4M）。3M净利率更高（10.8% vs -8.0%，领先18.8%）。ANGIODYNAMICS INC同比增速更快（9.0% vs 1.3%）。3M自由现金流更多（$2.0B vs $4.2M）。过去两年ANGIODYNAMICS INC的营收复合增速更高（2.8% vs -1.8%）
AngioDynamics是一家全球医疗技术企业，专注于研发、生产及销售微创医疗设备，核心产品覆盖血管通路、外科消融、肿瘤治疗等领域，面向北美、欧洲、亚太地区的医院、门诊手术中心及各类医疗机构提供服务。
3M是美国知名跨国综合企业，业务覆盖工业、劳动者安全防护、消费品等多个领域，总部位于圣保罗郊区的枫木市。公司现有超6万款产品，涵盖胶粘剂、研磨材料、防火防护产品、个人防护装备、窗膜、车漆保护膜、电子连接绝缘材料、汽车养护产品、光学膜等品类。
ANGO vs MMM — 直观对比
营收规模更大
MMM
是对方的75.9倍
$79.4M
营收增速更快
ANGO
高出7.7%
1.3%
净利率更高
MMM
高出18.8%
-8.0%
自由现金流更多
MMM
多$2.0B
$4.2M
两年增速更快
ANGO
近两年复合增速
-1.8%
损益表 — Q2 2026 vs Q1 2026
| 指标 | | |
|---|---|---|
| 营收 | $79.4M | $6.0B |
| 净利润 | $-6.3M | $653.0M |
| 毛利率 | 56.4% | 40.7% |
| 营业利润率 | -7.7% | 23.2% |
| 净利率 | -8.0% | 10.8% |
| 营收同比 | 9.0% | 1.3% |
| 净利润同比 | 40.9% | -41.5% |
| 每股收益（稀释后） | $-0.15 | $1.23 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ANGOMMM
| Q1 26 | — | $6.0B | ||
| Q4 25 | $79.4M | $6.1B | ||
| Q3 25 | $75.7M | $6.5B | ||
| Q2 25 | $80.2M | $6.3B | ||
| Q1 25 | $72.0M | $6.0B | ||
| Q4 24 | $72.8M | $6.0B | ||
| Q3 24 | $67.5M | $6.3B | ||
| Q2 24 | $71.0M | $6.3B |
净利润ANGOMMM
| Q1 26 | — | $653.0M | ||
| Q4 25 | $-6.3M | $577.0M | ||
| Q3 25 | $-10.9M | $834.0M | ||
| Q2 25 | $-6.0M | $723.0M | ||
| Q1 25 | $-4.4M | $1.1B | ||
| Q4 24 | $-10.7M | $728.0M | ||
| Q3 24 | $-12.8M | $1.4B | ||
| Q2 24 | $-13.4M | $1.1B |
毛利率ANGOMMM
| Q1 26 | — | 40.7% | ||
| Q4 25 | 56.4% | 33.6% | ||
| Q3 25 | 55.3% | 41.8% | ||
| Q2 25 | 52.7% | 42.5% | ||
| Q1 25 | 54.0% | 41.6% | ||
| Q4 24 | 54.8% | 51.7% | ||
| Q3 24 | 54.4% | 42.1% | ||
| Q2 24 | 54.3% | 42.9% |
营业利润率ANGOMMM
| Q1 26 | — | 23.2% | ||
| Q4 25 | -7.7% | 13.0% | ||
| Q3 25 | -14.1% | 22.2% | ||
| Q2 25 | -7.2% | 18.0% | ||
| Q1 25 | -13.9% | 20.9% | ||
| Q4 24 | -15.2% | 12.2% | ||
| Q3 24 | -19.4% | 20.9% | ||
| Q2 24 | -20.4% | 20.3% |
净利率ANGOMMM
| Q1 26 | — | 10.8% | ||
| Q4 25 | -8.0% | 9.4% | ||
| Q3 25 | -14.4% | 12.8% | ||
| Q2 25 | -7.5% | 11.4% | ||
| Q1 25 | -6.1% | 18.7% | ||
| Q4 24 | -14.7% | 12.1% | ||
| Q3 24 | -19.0% | 21.8% | ||
| Q2 24 | -18.9% | 18.3% |
每股收益（稀释后）ANGOMMM
| Q1 26 | — | $1.23 | ||
| Q4 25 | $-0.15 | $1.07 | ||
| Q3 25 | $-0.26 | $1.55 | ||
| Q2 25 | $-0.15 | $1.34 | ||
| Q1 25 | $-0.11 | $2.04 | ||
| Q4 24 | $-0.26 | $1.33 | ||
| Q3 24 | $-0.31 | $2.48 | ||
| Q2 24 | $-0.35 | $2.07 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $41.6M | $3.7B |
| 总债务越低越好 | — | $10.9B |
| 股东权益账面价值 | $176.3M | $3.3B |
| 总资产 | $269.7M | $35.4B |
| 负债/权益比越低杠杆越低 | — | 3.29× |
8季度趋势，按日历期对齐
现金及短期投资ANGOMMM
| Q1 26 | — | $3.7B | ||
| Q4 25 | $41.6M | — | ||
| Q3 25 | $38.8M | — | ||
| Q2 25 | $55.9M | — | ||
| Q1 25 | $44.8M | — | ||
| Q4 24 | $54.1M | — | ||
| Q3 24 | $55.0M | — | ||
| Q2 24 | $76.1M | — |
总债务ANGOMMM
| Q1 26 | — | $10.9B | ||
| Q4 25 | — | $12.6B | ||
| Q3 25 | — | $12.6B | ||
| Q2 25 | — | $13.1B | ||
| Q1 25 | — | $13.5B | ||
| Q4 24 | — | $13.0B | ||
| Q3 24 | — | $13.2B | ||
| Q2 24 | $0 | $13.1B |
股东权益ANGOMMM
| Q1 26 | — | $3.3B | ||
| Q4 25 | $176.3M | $4.7B | ||
| Q3 25 | $178.9M | $4.6B | ||
| Q2 25 | $183.0M | $4.3B | ||
| Q1 25 | $185.9M | $4.5B | ||
| Q4 24 | $186.8M | $3.8B | ||
| Q3 24 | $196.6M | $4.6B | ||
| Q2 24 | $205.6M | $3.9B |
总资产ANGOMMM
| Q1 26 | — | $35.4B | ||
| Q4 25 | $269.7M | $37.7B | ||
| Q3 25 | $265.6M | $37.6B | ||
| Q2 25 | $280.1M | $38.0B | ||
| Q1 25 | $285.4M | $40.0B | ||
| Q4 24 | $291.6M | $39.9B | ||
| Q3 24 | $293.6M | $40.9B | ||
| Q2 24 | $317.7M | $43.4B |
负债/权益比ANGOMMM
| Q1 26 | — | 3.29× | ||
| Q4 25 | — | 2.68× | ||
| Q3 25 | — | 2.72× | ||
| Q2 25 | — | 3.06× | ||
| Q1 25 | — | 3.02× | ||
| Q4 24 | — | 3.40× | ||
| Q3 24 | — | 2.84× | ||
| Q2 24 | 0.00× | 3.34× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $4.7M | — |
| 自由现金流经营现金流 - 资本支出 | $4.2M | $2.0B |
| 自由现金流率自由现金流/营收 | 5.3% | 33.6% |
| 资本支出强度资本支出/营收 | 0.5% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-9.3M | $3.7B |
8季度趋势，按日历期对齐
经营现金流ANGOMMM
| Q1 26 | — | — | ||
| Q4 25 | $4.7M | $1.6B | ||
| Q3 25 | $-15.9M | $1.8B | ||
| Q2 25 | $18.8M | $-954.0M | ||
| Q1 25 | $-13.2M | $-79.0M | ||
| Q4 24 | $2.5M | $1.8B | ||
| Q3 24 | $-18.3M | $-1.8B | ||
| Q2 24 | $5.0M | $1.0B |
自由现金流ANGOMMM
| Q1 26 | — | $2.0B | ||
| Q4 25 | $4.2M | $1.3B | ||
| Q3 25 | $-16.6M | $1.5B | ||
| Q2 25 | $18.0M | $-1.2B | ||
| Q1 25 | $-15.0M | $-315.0M | ||
| Q4 24 | $1.7M | $1.5B | ||
| Q3 24 | $-19.3M | $-2.0B | ||
| Q2 24 | $4.4M | $752.0M |
自由现金流率ANGOMMM
| Q1 26 | — | 33.6% | ||
| Q4 25 | 5.3% | 21.8% | ||
| Q3 25 | -22.0% | 23.6% | ||
| Q2 25 | 22.5% | -18.3% | ||
| Q1 25 | -20.8% | -5.3% | ||
| Q4 24 | 2.3% | 25.4% | ||
| Q3 24 | -28.7% | -32.3% | ||
| Q2 24 | 6.2% | 12.0% |
资本支出强度ANGOMMM
| Q1 26 | — | — | ||
| Q4 25 | 0.5% | 4.0% | ||
| Q3 25 | 1.0% | 3.3% | ||
| Q2 25 | 1.0% | 3.3% | ||
| Q1 25 | 2.5% | 4.0% | ||
| Q4 24 | 1.1% | 4.8% | ||
| Q3 24 | 1.6% | 3.9% | ||
| Q2 24 | 0.8% | 4.3% |
现金转化率ANGOMMM
| Q1 26 | — | — | ||
| Q4 25 | — | 2.74× | ||
| Q3 25 | — | 2.11× | ||
| Q2 25 | — | -1.32× | ||
| Q1 25 | — | -0.07× | ||
| Q4 24 | — | 2.50× | ||
| Q3 24 | — | -1.30× | ||
| Q2 24 | — | 0.89× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ANGO
| Med Device | $37.2M | 47% |
| Med Tech | $30.4M | 38% |
| Other | $11.8M | 15% |
MMM
| Safety and Industrial business segment | $2.9B | 49% |
| Transportation and Electronics business segment | $1.8B | 31% |
| Consumer business segment | $1.1B | 19% |
| Corporate | $121.0M | 2% |
